Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005

被引:132
作者
Kobayashi, Intetsu [1 ]
Murakami, Kazunari [2 ]
Kato, Mototsugu [3 ]
Kato, Seiichi [4 ]
Azuma, Takeshi [5 ]
Takahashi, Shin'ichi [6 ]
Uemura, Naomi [7 ]
Katsuyama, Tsutomu [8 ]
Fukuda, Yoshihiro [9 ]
Haruma, Ken [10 ]
Nasu, Masaru [11 ]
Fujioka, Toshio [12 ]
机构
[1] Mitsubishi Chem Med Corp, Chemotherapy Div, Itabashi Ku, Tokyo 1748555, Japan
[2] Oita Univ, Fac Med, Dept Gastroenterol, Oita 8795593, Japan
[3] Hokkaido Univ Hosp, Div Endoscopy, Kita Ku, Sapporo, Hokkaido 0600814, Japan
[4] Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, Sendai, Miyagi 9808574, Japan
[5] Kobe Univ, Sch Med, Dept Gastroenterol, Chuo Ku, Kobe, Hyogo 6500017, Japan
[6] Kyorin Univ, Sch Med, Dept Internal Med, Mitaka, Tokyo 1818611, Japan
[7] Ctr Internal Med, Dept Gastroenterol, Shinjuku Ku, Tokyo 1628655, Japan
[8] Shinshu Univ, Grad Sch Med, Lab Med, Matsumoto, Nagano 3908621, Japan
[9] Hyogo Coll Med, Nishinomiya, Hyogo 6638501, Japan
[10] Kawasaki Med Sch, Dept Internal Med, Div Gastroenterol, Kurashiki, Okayama 7010192, Japan
[11] Oita Nakamura Hosp, Gen Clin Res Ctr, Oita 8700022, Japan
[12] Oita Univ, Fac Med, Dept Gastroenterol, Oita 8795593, Japan
关键词
D O I
10.1128/JCM.00740-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Surveillance of Helicobacter pylori antimicrobial susceptibility reflecting the general population in Japan is limited. The antimicrobial susceptibilities of 3,707 H. pylori strains isolated from gastric mucosa samples of previously untreated patients diagnosed with gastroduodenal diseases at 36 medical facilities located throughout Japan between October 2002 and September 2005 were evaluated. Using an agar dilution method for antimicrobial susceptibility testing of H. pylori, the MIC distributions and trends during the study period for clarithromycin, amoxicillin, and metronidazole were studied. While the MIC (50) and MIC90 for clarithromycin did not change during the 3-year period, the MIC80 showed a 128-fold increase. Furthermore, the rate of resistance increased yearly from 18.9% (2002 to 2003) to 21.1% (2003 to 2004) and 27.7% (2004 to 2005). With a resistance rate of 19.2% among males compared to 27.0% among females, a significant gender difference was observed (P < 0.0001). Our study shows that in Japan, there is an evolving trend towards increased resistance to clarithromycin with geographical and gender differences as well as between clinical disease conditions. No significant changes in resistance were observed for amoxicillin and metronidazole during the period. While the benefit of H. pylori antimicrobial susceptibility testing has been debated in Japan, current empirical regimens are not based on susceptibility data representative of the general population. The development of an effective H. pylori eradication regimen in Japan will require continued resistance surveillance as well as a better understanding of the epidemiology of resistance.
引用
收藏
页码:4006 / 4010
页数:5
相关论文
共 28 条
  • [1] Antibiotic resistance problems with Helicobacter pylori
    Alarcón, T
    Domingo, D
    López-Brea, M
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 12 (01) : 19 - 26
  • [2] Aldana LP, 2002, HELICOBACTER, V7, P306
  • [3] [Anonymous], 1994, NIH Consens Statement, V12, P1
  • [4] [Anonymous], 2006, METH DIL ANT SUSC TE
  • [5] Guidelines in the management of Helicobacter pylori infection in Japan
    Asaka, M
    Satoh, K
    Sugano, K
    Sugiyama, T
    Takahashi, S
    Fukuda, Y
    Ota, H
    Murakami, K
    Kimura, K
    Shimoyama, T
    [J]. HELICOBACTER, 2001, 6 (03) : 177 - 186
  • [6] Prevalence of resistant Helicobacter pylori isolates in Bulgarian children
    Boyanova, L
    Koumanova, R
    Gergova, G
    Popova, M
    Mitov, I
    Kovacheva, Y
    Derejian, S
    Katsarov, N
    Nikolov, R
    Krastev, Z
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2002, 51 (09) : 786 - 790
  • [7] Clinical and Laboratory Standards Institute, 2006, M100S16 CLIN LAB STA
  • [8] Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States
    Duck, WM
    Sobel, J
    Pruckler, JM
    Song, OS
    Swerdlow, D
    Friedman, C
    Sulka, A
    Swaminathan, B
    Taylor, T
    Hoekstra, M
    Griffin, P
    Smoot, D
    Peek, R
    Metz, DC
    Bloom, PB
    Goldschmid, S
    Parsonnet, J
    Triadafilopoulos, G
    Perez-Perez, GI
    Vakil, N
    Ernst, P
    Czinn, S
    Dunne, D
    Gold, BD
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (06) : 1088 - 1094
  • [9] Furuta Takahisa, 2005, Drug Metab Pharmacokinet, V20, P153, DOI 10.2133/dmpk.20.153
  • [10] *JAP SOC CHEM, 2000, JPN SOC CHEMOTHER, V48, P561